Mednosis LogoMednosis

Ophthalmology & AI

RSS

AI for eye health: diabetic retinopathy screening, glaucoma detection, and retinal imaging analysis.

Why it matters: Millions face vision loss from diabetic retinopathy. AI screening can detect it early, even in areas without eye specialists.

Intravitreal photoswitch therapy in advanced retinitis pigmentosa: a phase 1 open-label trial
Nature Medicine - AI SectionExploratory3 min read

Injectable chemical therapy restores light sensitivity in blind patients

Key Takeaway:

Intravitreal photoswitch therapy, currently in early trials, shows promise in safely improving light response for patients with advanced retinitis pigmentosa.

In a Phase 1 open-label clinical trial, researchers tested a novel treatment called intravitreal photoswitch therapy on patients with advanced retinitis pigmentosa. This progressive genetic disease destroys the light-sensing cells in the retina, eventually causing total blindness. The therapy involves injecting a special chemical compound directly into the eye. This compound is designed to attach to remaining, non-sensory retinal cells and chemically turn them into active light detectors. The trial proved the injections were safe to administer and successfully showed early, promising signs of restored light responsiveness in the patients, offering a potential new pathway to bring back basic sight.

What this means for you

This early research shows promise for retinitis pigmentosa, but it's not yet available in clinics. It may take years before it's ready. Continue with your current care and consult your doctor for advice.

Citation:

Nature Medicine - AI Section, 2026. DOI: s41591-026-04317-6 Read article →

Guideline Update
Low-Vision Programmers Can Now Design 3D Models Independently
IEEE Spectrum - BiomedicalExploratory3 min read

Accessible 3D tools empower low-vision programmers

Key Takeaway:

New 3D modeling tools now allow low-vision programmers to independently create 3D models, improving accessibility in fields like healthcare that require precise design.

Researchers have developed innovative 3D modeling tools that allow low-vision programmers to design complex physical models independently. Historically, 3D design has been highly visual, creating massive barriers for visually impaired individuals in fields like biomedical engineering and prosthetic design. The new system combines physical haptic feedback devices with interactive audio cues, allowing users to feel and hear the shapes they are creating. By removing visual barriers, this tool enables low-vision designers to contribute directly to healthcare innovation and create custom medical devices.

What this means for you

Exciting research for low-vision individuals in 3D modeling, but it's still early. It may take years to become widely available. Continue following your current care plan and consult your doctor for guidance.

Citation:

IEEE Spectrum - Biomedical, 2026. Read article →

Guideline Update
Low-Vision Programmers Can Now Design 3D Models Independently
IEEE Spectrum - BiomedicalExploratory3 min read

New 3D design tools empower low-vision programmers

Key Takeaway:

New 3D modeling tools now allow low-vision programmers to independently create designs, significantly improving accessibility in technology and engineering fields.

Researchers have developed innovative 3D modeling tools designed specifically for low-vision programmers and engineers. Traditional 3D design software relies heavily on visual feedback, creating a massive barrier for visually impaired individuals trying to work in hardware design, robotics, and biomedical engineering. To solve this, the new tools incorporate non-visual interfaces, including auditory feedback and haptic touch technology. This advancement allows low-vision users to independently create complex 3D models, opening up career paths in engineering and ensuring that future medical technologies are designed by a more diverse group of creators.

What this means for you

Exciting early research allows low-vision programmers to design 3D models independently. It's not yet available for public use. Please continue following your current care plan and consult your doctor for guidance.

Citation:

IEEE Spectrum - Biomedical, 2026. Read article →